| Literature DB >> 16806467 |
A Martínez1, I Olarte, M A Mergold, M Gutiérrez, E Rozen, J Collazo, O Amancio-Chassin, R M Ordóñez, J J Montesinos, H Mayani, D K McCurdy, P Ostrosky-Wegman, E Garrido-Guerrero, E I Miranda.
Abstract
Leukemia-associated antigens such as proteins encoded by MAGE genes might provide tools for immunotherapy of leukemia. Positive and negative results of MAGE-A gene expression in hematological malignancies have been reported. This led us to study MAGE-A gene expression in human leukemias using RT-PCR. Among 115 leukemias from various subtypes, 14/34 (41.17%) AML were positive for one of the three genes analyzed (MAGE-A1 1/32; MAGE-A3 10/32; MAGE-B2 3/12). Expression was also detected in 23/76 (30.26%) B-cell ALL patients (MAGE-A1 2/53; MAGE-A3 20/53; MAGE-B2 1/32). One of these patients expressed both MAGE-A1 (weak signal) and -A3 (strong signal) genes. Other patient with CML were positive for MAGE-B2 (1/5, 20%). MAGE-A3 expression data were corroborated by real time RT-PCR through determination of MAGE-A3 transcript levels. We concluded that the MAGE-A3 gene is expressed at the mRNA level in a proportion of human leukemias.Entities:
Mesh：
Substances：
Year: 2006 PMID： 16806467 DOI： 10.1016/j.leukres.2006.05.009
Source DB: PubMed Journal: Leuk Res ISSN： 0145-2126 Impact factor: 3.156